Shopping Cart 0
Cart Subtotal
USD 0

Humanigen Inc (HGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodies, used for the treatment of solid tumors and their micro environment; and certain hematologic malignancies such as chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. It has developed the recombinant monoclonal antibodies using its proprietary drug discovery technology called Humaneered. Humanigen also provides data on on pharmacokinetics and pharmacodynamics including correlative biomarkers and mutational analysis for conducting studies in and juvenile myelomonocytic leukemia. Humanigen is headquartered in Brisbane, California, the US.

Humanigen Inc (HGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Humanigen Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11

Venture Financing 12

KaloBios Pharma Raises USD12.2 Million in Venture Financing 12

Kalobios Pharma Raises Additional USD 3 Million In Series E Financing 13

Partnerships 14

Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14

Equity Offering 15

Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15

KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16

KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17

KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18

KaloBios Pharma Completes Public Offering Of Shares For USD 34.5 Million 19

KaloBios Pharma Completes IPO For USD 70 Million 21

Acquisition 24

Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24

Humanigen Inc-Key Competitors 25

Humanigen Inc-Key Employees 26

Humanigen Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Mar 12, 2018: Humanigen Appoints Robert Savage to Board of Directors 28

Feb 07, 2018: Humanigen Names Rainer Boehm As Board Director 29

Aug 28, 2017: Humanigen Appoints Chief Financial Officer 30

Product News 31

04/06/2017: Benznidazole on Track in Progress to IND and NDA Submissions 31

Product Approvals 32

Jul 11, 2017: KaloBios Receives Orphan Drug Designation for Benznidazole in the Treatment of Chagas Disease 32

Jun 27, 2017: Benznidazole IND for Chagas Disease Receives Clearance by FDA 33

May 30, 2017: KaloBios Submits IND Application for Benznidazole to FDA 34

Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole 35

Clinical Trials 36

Aug 08, 2017: Humanigen Announces Completion of Benznidazole Bioavailability Study 36

Other Significant Developments 37

Aug 07, 2017: Humanigen is Effective Today 37

Jul 27, 2017: KaloBios To Change Company Name To Humanigen 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Humanigen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Humanigen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Humanigen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 11

KaloBios Pharma Raises USD12.2 Million in Venture Financing 12

Kalobios Pharma Raises Additional USD 3 Million In Series E Financing 13

Humanigen Enters into Research Agreement with MD Anderson Cancer Center 14

Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 15

KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 16

KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 17

KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 18

KaloBios Pharma Completes Public Offering Of Shares For USD 34.5 Million 19

KaloBios Pharma Completes IPO For USD 70 Million 21

Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 24

Humanigen Inc, Key Competitors 25

Humanigen Inc, Key Employees 26

Humanigen Inc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Humanigen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.